GS vs LLY: Which Is the Better Buy?
Side-by-side comparison of The Goldman Sachs Group, Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
The Goldman Sachs Group, Inc. · Financial Services
$926.55
-45.0% upside to fair value
Grade D
VS
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+17.6%).
GS trades at a lower forward P/E
(15.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GS |
LLY |
| Current Price |
$926.55 |
$934.34 |
| Fair Value Estimate |
$509.60 |
$1,098.43 |
| Upside to Fair Value |
-45.0%
|
+17.6%
|
| Market Cap |
$275.0B |
$882.8B |
| Forward P/E |
15.6x
|
33.1x
|
| EV / EBITDA |
30.6x
|
27.9x
|
| Price / Sales |
2.5x
|
12.2x
|
| Price / FCF |
-5.8x
|
65.0x
|
| Revenue Growth YoY |
-45.4%
|
+55.5%
|
| Gross Margin |
55.5%
|
82.7%
|
| Operating Margin |
20.5%
|
46.3%
|
| Return on Equity |
14.6%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
1.54%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
The Goldman Sachs Group, Inc. operates as a leading global financial services firm specializing in investment banking, securities, investment management, and consumer banking. The company benefits from a high-quality business model characterized by strong brand recognition, deep client relationships, and a history of stable leadership. However, the stock is currently significantly overvalued, tra…
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Accumulation Zones
| Metric |
GS |
LLY |
| Zone Low |
$382.20 |
$823.82 |
| Zone High |
$433.16 |
$933.67 |
| In Buy Zone? |
No
|
No
|